Evotec AG today announced the achievement of a key pre-clinical milestone in the ongoing alliance with its research partner Padlock Therapeutics, Inc. („Padlock“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-milestone-in-collaboration-with-padlock-therapeutics-5346
Evotec to present at IR conference
Hamburg, Germany – 03 March 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its CEO, Dr Werner Lanthaler, will present at the BioCapital Europe 2016 in Amsterdam, The Netherlands, … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-present-at-ir-conference-5344
The preclinical clinical interface: A key to translational success in Oncology
Evotecs nächstes Webinar “The preclinical clinical interface: A key to translational success in Oncology” findet am Donnerstag, den 10. März 2016 um 10.00 Uhr EST / 15.00 Uhr GMT statt und wird unter anderem … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/the-preclinical-clinical-interface-a-key-to-translational-success-in-oncology-5340
Evotec awarded grant from The Michael J. Fox Foundation for Parkinson's Research
Evotec AG today announced that it has been awarded a research grant from The Michael J. Fox Foundation („MJFF“) to further develop Evotec’s TargetaSN (Targetalpha-synuclein) programme for the treatment of Parkinson’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-awarded-grant-from-the-michael-j-fox-foundation-for-parkinsons-research-5339
Evotec achieves important milestone in TargetAD collaboration with Janssen in Alzheimer's disease
Evotec AG today announced the achievement of an important milestone in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. („Janssen“) for the transition of a project into further drug discovery process. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-important-milestone-in-targetad-collaboration-with-janssen-in-alzheimers-disease-5335
Evotec and UCB sign multi-year sample management agreement
Evotec AG today announced an EVT Execute collaboration aimed at providing a complete solution to UCB’s global sample management requirements. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-ucb-sign-multi-year-sample-management-agreement-5333
Evotec and Spero Therapeutics extend collaboration to develop novel antibacterials
Evotec AG today announced an extension of an existing collaboration with Spero Therapeutics, based in Cambridge, Massachusetts, aimed at discovering and developing new and ground-breaking therapeutics for Gram-negative bacteria to treat serious infections and address the growing threat to global public health resulting from antibiotic resistance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-spero-therapeutics-extend-collaboration-to-develop-novel-antibacterials-10
Evotec receives important pre-clinical milestones as part of its multi-target alliance with Bayer HealthCare
Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached two important pre-clinical milestones for the transition of two projects from the alliance portfolio into late-stage discovery and pre-clinical development for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-important-pre-clinical-milestones-as-part-of-its-multi-target-alliance-with-bayer-healthcare-11
Huntington’s disease and the hope for a treatment
Hamburg, Germany – 20 November 2015: Evotec announced that Charles Sabine, former Emmy-awarded NBC News journalist and a high-profile spokesman for the global Huntington’s disease community, gave a lecture on “Why … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/huntingtons-disease-and-the-hope-for-a-treatment-5324
Evotec AG reports results of the first nine months of 2015
– STRONG GROWTH IN REVENUES AND PROFITS – THREE MAJOR EVT INNOVATE DEALS CONCLUDED – REVENUE GUIDANCE RAISED ON 15 SEPTEMBER 2015 Hamburg, Germany – 10 November 2015: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-the-first-nine-months-of-2015-5321